title: Neoadjuvant hormonal therapy in prostate cancer - impact of PSA level before radiotherapy.
abstract: OBJECTIVE
  To retrospectively investigate the impact of prostate specific antigen (PSA) level after neoadjuvant androgen- deprivation therapy (ADT) on biochemical relapse-free survival in patients with prostate cancer who received radical radiotherapy (RT).
  
  
  METHODS
  Between March 2003 and March 2008, 128 men with localized prostate cancer underwent neoadjuvant ADT for 4-6 months followed by radical RT. Biochemical relapse-free survival was compared between patients with pre-RT PSA ≤ 0.1 vs > 0.1 ng/mL.
  
  
  RESULTS
  At a median follow up of 47.3 months, biochemical relapse-free survival was significantly higher in patients with a pre-RT PSA ≤ 0.1 ng/mL compared with pre-RT PSA > 0.1 ng/mL (85.6 vs 63.2%, p = 0.0025).
  
  
  CONCLUSIONS
  The current analysis demonstrating better treatment outcome in patients with excellent biochemical response to neoadjuvant ADT, supports an individualized treatment strategy.
authors.affiliation: Oncology Centre, Multiscan α Pardubice Regional Hospital, Pardubice, Czech Republic.
authors.forename: M
authors.initials: M
authors.lastname: Dolezel
authors.forename: K
authors.initials: K
authors.lastname: Odrazka
authors.forename: J
authors.initials: J
authors.lastname: Vanasek
authors.forename: M
authors.initials: M
authors.lastname: Vaculikova
authors.forename: J
authors.initials: J
authors.lastname: Vlkova-Sefrova
authors.forename: J
authors.initials: J
authors.lastname: Jansa
authors.forename: Z
authors.initials: Z
authors.lastname: Macingova
authors.forename: M
authors.initials: M
authors.lastname: Brodak
authors.forename: I
authors.initials: I
authors.lastname: Hartmann
authors.forename: B
authors.initials: B
authors.lastname: Melichar
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D006801:Humans; D007610:Kallikreins / Q000097:blood*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D060787:Neoplasm Grading; D018579:Patient Selection; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology / Q000532:radiotherapy*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal; C549870:KLK3 protein, human; D007610:Kallikreins; D017430:Prostate-Specific Antigen